Obstructive sleep apnoea: does one treatment not fit all?

[1]  P. van de Heyning,et al.  Upper-airway stimulation for obstructive sleep apnea. , 2014, The New England journal of medicine.

[2]  Z. Topor,et al.  Remotely controlled mandibular protrusion during sleep predicts therapeutic success with oral appliances in patients with obstructive sleep apnea. , 2013, Sleep.

[3]  D. Hsiang,et al.  Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  G. Marks,et al.  Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. , 2013, American journal of respiratory and critical care medicine.

[5]  M. Goetting,et al.  [Upper airway stimulation in obstructive sleep apnea]. , 2014, Laryngo- rhino- otologie.

[6]  Shinji Takeuchi,et al.  Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells , 2012, Clinical Cancer Research.

[7]  Susan Redline,et al.  CPAP versus oxygen in obstructive sleep apnea. , 2014, The New England journal of medicine.

[8]  A. Malhotra,et al.  Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. , 2013, American journal of respiratory and critical care medicine.

[9]  A. Malhotra,et al.  Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. , 2011, Clinical science.

[10]  Swastik Agrawal,et al.  CPAP for the metabolic syndrome in patients with obstructive sleep apnea. , 2011, The New England journal of medicine.

[11]  J. Acquaviva,et al.  The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. , 2009, Biochimica et biophysica acta.

[12]  T. Wadden,et al.  CPAP, weight loss, or both for obstructive sleep apnea. , 2014, The New England journal of medicine.

[13]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[14]  R. Grunstein,et al.  Adherence to Continuous Positive Airway Pressure Therapy , 2012 .

[15]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[16]  A. Iafrate,et al.  Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib , 2014, Clinical Cancer Research.

[17]  B. Edwards,et al.  Effects of hyperoxia and hypoxia on the physiological traits responsible for obstructive sleep apnoea , 2014, The Journal of physiology.

[18]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.